Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
Condition(s):CD30 Positive Primary Mediastinal Large B-cell Lymphoma; CD30-Positive Diffuse Large B-Cell Lymphoma; CD30-Positive Gray Zone LymphomaLast Updated:January 5, 2021Completed